 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Bone Metastasis
| AMG 162 |
Monoclonal antibody RANK ligand inhibitor |
Amgen |
III |
| Bonviva (ibandronate) |
Bisphosphonate |
Roche and GlaxoSmithKline |
III |
| CAL |
Humanized anti PTHrP MoAb |
Chigai Pharmaceuticals |
II |
| Zometa (zoledronic acid) |
Bisphosphonate |
Novartis |
Approved and phase III |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
